{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:07:47Z","timestamp":1781078867020,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,10]]},"DOI":"10.7759\/cureus.110570","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:49:28Z","timestamp":1781077768000},"source":"Crossref","is-referenced-by-count":0,"title":["Individualizing Injectable Testosterone Replacement Therapy in Primary Care: Pharmacokinetics, Symptom Stability, Safety Monitoring, and Injection Frequency"],"prefix":"10.7759","author":[{"given":"Khashayar","family":"Farzam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline","volume":"103","author":"Bhasin S","year":"2018","unstructured":"Bhasin S, Brito JP, Cunningham GR, et al.. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018, 103:1715-44. 10.1210\/jc.2018-00229","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and management of testosterone deficiency: AUA guideline","volume":"200","author":"Mulhall JP","year":"2018","unstructured":"Mulhall JP, Trost LW, Brannigan RE, et al.. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018, 200:423-32. 10.1016\/j.juro.2018.03.115","journal-title":"J Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.7252","article-title":"Canadian Urological Association clinical practice guideline on testosterone deficiency in men: evidence-based Q&A","volume":"15","author":"Grober ED","year":"2021","unstructured":"Grober ED, Krakowsky Y, Khera M, et al.. Canadian Urological Association clinical practice guideline on testosterone deficiency in men: evidence-based Q&amp;A. Can Urol Assoc J. 2021, 15:E234-43. 10.5489\/cuaj.7252","journal-title":"Can Urol Assoc J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.221027","article-title":"The British Society for Sexual Medicine guidelines on male adult testosterone deficiency, with statements for practice","volume":"41","author":"Hackett G","year":"2023","unstructured":"Hackett G, Kirby M, Rees RW, et al.. The British Society for Sexual Medicine guidelines on male adult testosterone deficiency, with statements for practice. World J Mens Health. 2023, 41:508-37. 10.5534\/wjmh.221027","journal-title":"World J Mens Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/andr.13108","article-title":"Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age","volume":"10","author":"Pastuszak AW","year":"2022","unstructured":"Pastuszak AW, Gittelman M, Tursi JP, Jaffe JS, Schofield D, Miner MM. Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age. Andrology. 2022, 10:209-22. 10.1111\/andr.13108","journal-title":"Andrology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2016.07.10","article-title":"Pharmacology of testosterone replacement therapy preparations","volume":"5","author":"Shoskes JJ","year":"2016","unstructured":"Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016, 5:834-43. 10.21037\/tau.2016.07.10","journal-title":"Transl Androl Urol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)59237-1","article-title":"Hormone kinetics after intramuscular testosterone cypionate","volume":"47","author":"Nankin HR","year":"1987","unstructured":"Nankin HR. Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril. 1987, 47:1004-9. 10.1016\/S0015-0282(16)59237-1","journal-title":"Fertil Steril"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.10.6078","article-title":"Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men","volume":"84","author":"Dobs AS","year":"1999","unstructured":"Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999, 84:3469-78. 10.1210\/jcem.84.10.6078","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","article-title":"Androgen receptor structure, function and biology: from bench to bedside","volume":"37","author":"Davey RA","year":"2016","unstructured":"Davey RA, Grossmann M. Androgen receptor structure, function and biology: from bench to bedside. Clin Biochem Rev. 2016, 37:3-15.","journal-title":"Clin Biochem Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1206168","article-title":"Gonadal steroids and body composition, strength, and sexual function in men","volume":"369","author":"Finkelstein JS","year":"2013","unstructured":"Finkelstein JS, Lee H, Burnett-Bowie SA, et al.. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013, 369:1011-22. 10.1056\/NEJMoa1206168","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84137","article-title":"Gonadal steroid-dependent effects on bone turnover and bone mineral density in men","volume":"126","author":"Finkelstein JS","year":"2016","unstructured":"Finkelstein JS, Lee H, Leder BZ, et al.. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest. 2016, 126:1114-25. 10.1172\/JCI84137","journal-title":"J Clin Invest"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0739","article-title":"Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels","volume":"94","author":"Burnett-Bowie SA","year":"2009","unstructured":"Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009, 94:4785-92. 10.1210\/jc.2009-0739","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/andr.12126","article-title":"Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized-controlled trial","volume":"4","author":"Dias JP","year":"2016","unstructured":"Dias JP, Melvin D, Simonsick EM, et al.. Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized-controlled trial. Andrology. 2016, 4:33-40. 10.1111\/andr.12126","journal-title":"Andrology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glt154","article-title":"Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin\/hemoglobin set point","volume":"69","author":"Bachman E","year":"2014","unstructured":"Bachman E, Travison TG, Basaria S, et al.. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin\/hemoglobin set point. J Gerontol A Biol Sci Med Sci. 2014, 69:725-35. 10.1093\/gerona\/glt154","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0864","article-title":"Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis","volume":"95","author":"Bachman E","year":"2010","unstructured":"Bachman E, Feng R, Travison T, et al.. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab. 2010, 95:4743-7. 10.1210\/jc.2010-0864","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2017.04.001","article-title":"Erythrocytosis following testosterone therapy","volume":"6","author":"Ohlander SJ","year":"2018","unstructured":"Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018, 6:77-85. 10.1016\/j.sxmr.2017.04.001","journal-title":"Sex Med Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/sm2.76","article-title":"Comparison of the effects of testosterone gels, injections, and pellets on serum hormones, erythrocytosis, lipids, and prostate-specific antigen","volume":"3","author":"Pastuszak AW","year":"2015","unstructured":"Pastuszak AW, Gomez LP, Scovell JM, Khera M, Lamb DJ, Lipshultz LI. Comparison of the effects of testosterone gels, injections, and pellets on serum hormones, erythrocytosis, lipids, and prostate-specific antigen. Sex Med. 2015, 3:165-73. 10.1002\/sm2.76","journal-title":"Sex Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1530\/EC-24-0283","article-title":"Testosterone therapy-induced erythrocytosis: can phlebotomy be justified?","volume":"13","author":"Bond P","year":"2024","unstructured":"Bond P, Verdegaal T, Smit DL. Testosterone therapy-induced erythrocytosis: can phlebotomy be justified?. Endocr Connect. 2024, 13:10.1530\/EC-24-0283","journal-title":"Endocr Connect"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/smrj.43","article-title":"Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male","volume":"3","author":"Jones SD Jr","year":"2015","unstructured":"Jones SD Jr, Dukovac T, Sangkum P, Yafi FA, Hellstrom WJ. Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. Sex Med Rev. 2015, 3:101-12. 10.1002\/smrj.43","journal-title":"Sex Med Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000119417","article-title":"Testosterone and blood pressure regulation","volume":"31","author":"Kienitz T","year":"2008","unstructured":"Kienitz T, Quinkler M. Testosterone and blood pressure regulation. Kidney Blood Press Res. 2008, 31:71-9. 10.1159\/000119417","journal-title":"Kidney Blood Press Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/817835","article-title":"Testosterone increases: sodium reabsorption, blood pressure, and renal pathology in female spontaneously hypertensive rats on a high sodium diet","volume":"2011","author":"Liu B","year":"2011","unstructured":"Liu B, Ely D. Testosterone increases: sodium reabsorption, blood pressure, and renal pathology in female spontaneously hypertensive rats on a high sodium diet. Adv Pharmacol Sci. 2011, 2011:817835. 10.1155\/2011\/817835","journal-title":"Adv Pharmacol Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0553","article-title":"Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men","volume":"90","author":"Johannsson G","year":"2005","unstructured":"Johannsson G, Gibney J, Wolthers T, Leung KC, Ho KK. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J Clin Endocrinol Metab. 2005, 90:3989-94. 10.1210\/jc.2005-0553","journal-title":"J Clin Endocrinol Metab"},{"key":"ref23","unstructured":"FDA issues class-wide labeling changes for testosterone products. (2025). Accessed. May 11, 2026: https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-issues-class-wide-labeling-changes-testosterone-products."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-108","article-title":"Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials","volume":"11","author":"Xu L","year":"2013","unstructured":"Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013, 11:108. 10.1186\/1741-7015-11-108","journal-title":"BMC Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102588","article-title":"Effects of testosterone therapy in adult males with hypogonadism and T2DM: A meta-analysis and systematic review","volume":"16","author":"Kumar S","year":"2022","unstructured":"Kumar S, Khatri M, Memon RA, et al.. Effects of testosterone therapy in adult males with hypogonadism and T2DM: A meta-analysis and systematic review. Diabetes Metab Syndr. 2022, 16:102588. 10.1016\/j.dsx.2022.102588","journal-title":"Diabetes Metab Syndr"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000880","article-title":"Testosterone and male contraception","volume":"31","author":"Thirumalai A","year":"2024","unstructured":"Thirumalai A, Page ST. Testosterone and male contraception. Curr Opin Endocrinol Diabetes Obes. 2024, 31:236-42. 10.1097\/MED.0000000000000880","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.180036","article-title":"Testosterone is a contraceptive and should not be used in men who desire fertility","volume":"37","author":"Patel AS","year":"2019","unstructured":"Patel AS, Leong JY, Ramos L, Ramasamy R. Testosterone is a contraceptive and should not be used in men who desire fertility. World J Mens Health. 2019, 37:45-54. 10.5534\/wjmh.180036","journal-title":"World J Mens Health"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2223-4683.2013.06.01","article-title":"Exogenous testosterone: a preventable cause of male infertility","volume":"2","author":"Crosnoe LE","year":"2013","unstructured":"Crosnoe LE, Grober E, Ohl D, Kim ED. Exogenous testosterone: a preventable cause of male infertility. Transl Androl Urol. 2013, 2:106-13. 10.3978\/j.issn.2223-4683.2013.06.01","journal-title":"Transl Androl Urol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666201207104340","article-title":"Suppression of spermatogenesis by exogenous testosterone","volume":"27","author":"Fusco F","year":"2021","unstructured":"Fusco F, Verze P, Capece M, Napolitano L. Suppression of spermatogenesis by exogenous testosterone. Curr Pharm Des. 2021, 27:2750-3. 10.2174\/1381612826666201207104340","journal-title":"Curr Pharm Des"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1210\/er.2017-00025","article-title":"A reappraisal of testosterone's binding in circulation: physiological and clinical implications","volume":"38","author":"Goldman AL","year":"2017","unstructured":"Goldman AL, Bhasin S, Wu FC, Krishna M, Matsumoto AM, Jasuja R. A reappraisal of testosterone's binding in circulation: physiological and clinical implications. Endocr Rev. 2017, 38:302-24. 10.1210\/er.2017-00025","journal-title":"Endocr Rev"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab772","article-title":"Testosterone therapy with subcutaneous injections: a safe, practical, and reasonable option","volume":"107","author":"Figueiredo MG","year":"2022","unstructured":"Figueiredo MG, Gagliano-Juc\u00e1 T, Basaria S. Testosterone therapy with subcutaneous injections: a safe, practical, and reasonable option. J Clin Endocrinol Metab. 2022, 107:614-26. 10.1210\/clinem\/dgab772","journal-title":"J Clin Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00359","article-title":"Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients","volume":"102","author":"Spratt DI","year":"2017","unstructured":"Spratt DI, Stewart II, Savage C, et al.. Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: demonstration in female-to-male transgender patients. J Clin Endocrinol Metab. 2017, 102:2349-55. 10.1210\/jc.2017-00359","journal-title":"J Clin Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/sm2.80","article-title":"Pharmacokinetic profile of subcutaneous testosterone enanthate delivered via a novel, prefilled single-use autoinjector: a phase II study","volume":"3","author":"Kaminetsky J","year":"2015","unstructured":"Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic profile of subcutaneous testosterone enanthate delivered via a novel, prefilled single-use autoinjector: a phase II study. Sex Med. 2015, 3:269-79. 10.1002\/sm2.80","journal-title":"Sex Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Bhasin S, Flevaris P, et al.. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023, 389:107-17. 10.1056\/NEJMoa2215025","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/500148-individualizing-injectable-testosterone-replacement-therapy-in-primary-care-pharmacokinetics-symptom-stability-safety-monitoring-and-injection-frequency","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:49:35Z","timestamp":1781077775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/500148-individualizing-injectable-testosterone-replacement-therapy-in-primary-care-pharmacokinetics-symptom-stability-safety-monitoring-and-injection-frequency"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.110570","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}